Kyowa Kirin ploughed ahead with KW-6356 despite the reservations of its former partner Lundbeck, which held the rights to KW-6356 outside Asia before handing them back to the Japanese company.
Under the deal, Kyowa Kirin will pay BridgeBio $100M upfront, plus royalties up to a high-20s percentage on sales of the product in Japan and potential milestone payments.
Kura Oncology (KURA) and Kyowa Kirin announced topline results from KOMET-001, the Phase 2 registration-directed trial of ziftomenib, a highly ...
The Japanese pharmaceutical company Kyowa Kirin Co. plans to sell shares in the Chinese division of the Hong Kong company WinHealth Pharma Group Co. for 15 billion yen ($100 million) as part of the ...
The enhanced partnership provides enterprise-wide access to AlphaMeld Corporation’s proprietary AI-powered AlphaMeld ® platform, further accelerating Kyowa Kirin’s innovative drug discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback